Beslutningsforum introduced all five methods considered at its 16 November meeting.
The decisions included:
-
Pirtobrutinib (Jaypirca) as monotherapy for adults with relapsed or refractory chronic lymphocytic leukaemia.
-
Pirtobrutinib for adults with relapsed or refractory mantle cell lymphoma previously treated with a Bruton’s tyrosine kinase inhibitor. This followed a new supplier price offer; the treatment had previously been rejected twice because the price was not proportionate to benefit.
-
Brentuximab vedotin (Adcetris) for a subgroup of adults with previously untreated Hodgkin lymphoma, mainly patients of reproductive age who wish to have children.
-
Risankizumab (Skyrizi) for children with moderate-to-severe plaque psoriasis, extending an existing adult indication.
-
Daratumumab (Darzalex) with cyclophosphamide, bortezomib and dexamethasone for adults with systemic AL amyloidosis.
Daratumumab combination treatment had been temporarily introduced in 2024 pending study results. Beslutningsforum states that final results support earlier findings and show that the treatment effect is maintained over time.
Read more at https://www.nyemetoder.no/aktuelt/innforer-ny-behandling-av-leukemi/
